zPREDICTA
San Jose
About zPREDICTA
zPREDICTA’s bio-simulation technology combines biology with automation and computation to automate drug development. zPREDICTA's bio-simulation platform enables pharma to rapidly identify drug candidates that will be effective in patients. r-Organ is a set of next generation 3D culture models that provide 1-to-1 reconstruction of human tissue microenvironment in an organ- and disease-specific manner allowing accurate prediction of drug response. Utilizing r-Organ technology, zPREDICTA is mapping cellular behavior in response to anticancer drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $100.0K
- Funding stage: M&A
- Last round: Seed (Jun 2016)
- Website: zpredicta.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/zpredicta-121232 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.